I am excited by the prospects of synaptic regeneration in glaucoma and the opportunity to act as a science advisor to Spinogenix as they begin advancing SPG302 for the treatment of glaucoma.” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback